Latest from Maria, as of Thursday June 20
youtu.be/X_vW360U094?si=ByD...
Latest from Maria, as of Friday June 14
Latest from Maria, as of Thursday June 20
youtu.be/X_vW360U094?si=ByD...
Latest from Maria, as of Friday June 14
I actually signed up to be on the zoom call today! I am a Parkinson’s patient, I was on the trial last year, and I have invested in a small number of their stocks! Mainly because I am hoping they will do well! I’d really like to go back on the drug.
No news on Buntanetap in Parkinsons on the webcast. 😣 It was all about their results and plans for a new study in AD. They did say that if/when they do their new study in AD that they will also include an open label arm in that study which will last 18 months.
Dr Maccecchini took only 2 questions. One was where is the PD data. I heard was that results would be " in a few weeks" . There was a bit more dissembling about no company being able to show improvement in UPDRS II but little more.
Not really OK when the data is 6 months late (from original estimates)
Looks like they did not present anything on the Parkinson's study today June 11, 2024 during the webcast but I was not actually at there.
Here are the slides that were presented for the Alzheimer's study/data - not sure if the link will work as I got it off of my Fidelity website.
archive.fast-edgar.com/2024...
I don't know why the "data cleaning" is taking so much time
I believe Annovis Bio is significantly better at attracting investors than treating Parkinson's Disease.
i think it’s a win for all of us that it gets the green flag for Alzaheimer’s disease, tell me if I’m right. Say it’s works for AD, after it gains usage could it be prescribed by a doctor for a related illness such as gabapentin. If the results are good could it gain a foot hold like this?